Ennaid Therapeutics

Ennaid Therapeutics is a private U.S. biotechnology company focused on antiviral drug discovery and development for emerging infectious diseases. The company has described a patented anti-flavivirus platform built around modified peptide-based inhibitors aimed at blocking Zika and dengue viral entry, and it has also reported using AI-based drug discovery capabilities to identify repurposed antiviral candidates. Its disclosed pipeline has centered on dengue, Zika, West Nile virus, and COVID-19, with ENU200 highlighted as a repurposed oral antiviral candidate for mild to moderate COVID-19. Ennaid has also described two subsidiaries: Ennaid Drug Development, focused on infectious disease therapeutics, and Ennaid Healthcare IT/Digital Health, focused on computer vision and eye-tracking applications in healthcare. Publicly available evidence suggests the company remains active as a private early-stage firm, but there is no clear evidence of clinical-stage advancement or marketed products.